CompletedNCT02604420
Identification and Treatment of Thrombotic Microangiopathies in Allogeneic Stem Cell Transplants
Studying Thrombotic microangiopathy
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Weill Medical College of Cornell University
- Principal Investigator
- Jeffrey Laurence, MDWeill Medical College of Cornell University
- Intervention
- eculizumab(drug)
- Enrollment
- 200 target
- Eligibility
- 18-65 years · All sexes
- Timeline
- 2014 – 2018
Study locations (1)
- New York Presbyterian Hospital, New York, New York, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02604420 on ClinicalTrials.govOther trials for Thrombotic microangiopathy
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT07059026Thrombotic Microangiopathy (TMA) Associated With Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) In Adult PatientsITAC (Instituto de Trasplantes y Alta Complejidad)
- RECRUITINGNCT06102694Identification of Plasma Biomarkers for Early Diagnosis of Transplant-associated Thrombotic MicroangiopathyInstitute of Hematology & Blood Diseases Hospital, China
- RECRUITINGPHASE4NCT05743400Thymoglobulin® Pharmacokinetics in Patients Undergoing Hematopoietic Stem Cell TransplantationHospices Civils de Lyon
- RECRUITINGNCT06759961Post-transplant Thrombotic Microangiopathy: Evaluation of Outcomes at the Bologna Kidney Transplant CentreIRCCS Azienda Ospedaliero-Universitaria di Bologna
- ACTIVE NOT RECRUITINGPHASE3NCT04543591Ravulizumab in Thrombotic Microangiopathy After Hematopoietic Stem Cell TransplantAlexion Pharmaceuticals, Inc.